文献速递骨质疏松与钙磷/甲状旁腺

重组人甲状旁腺激素治疗成人甲状旁腺功能减退症5年安全性与疗效

Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

这项开放标签扩展研究评估了重组人PTH(1-84)治疗慢性甲状旁腺功能减退症成人患者(N=49)的长期安全性和耐受性。治疗相关不良事件常见但严重不良事件发生率为26.5%。

要点

  • rhPTH(1-84)治疗5年可维持血钙正常并改善尿钙、血磷等生化指标
  • 70.0%患者达到口服钙和骨化三醇剂量减少≥50%的复合疗效终点
  • 常见不良事件包括低钙血症、肌肉痉挛、感觉异常等,严重不良事件发生率26.5%

核心结论

  • rhPTH(1-84)治疗5年安全性特征与既往研究一致,并改善关键生化参数。

研究设计与样本

  • 开放标签扩展研究,5年中期分析,纳入美国12个中心的49例慢性甲状旁腺功能减退症成人患者。
  • 干预为rhPTH(1-84)初始25或50 µg/d,允许以25 µg调整,最大100 µg/d。

主要发现

  • 从基线至60个月,尿钙、血磷和钙磷乘积分别下降101.2 ± 236.24 mg/24小时、1.0 ± 0.78 mg/dL和8.5 ± 8.29 mg2/dL2。
  • 血清肌酐和估算肾小球滤过率无变化。
  • 治疗中出现不良事件48例(98.0%),常见低钙血症36.7%、肌肉痉挛32.7%、感觉异常30.6%、鼻窦炎30.6%、恶心30.6%;严重不良事件13例(26.5%)。
  • 第60个月时28例(70.0%)达到复合疗效终点,骨转换标志物升高约12个月达峰后下降但仍高于基线。

关键数值与推荐

  • 复合疗效终点定义为口服钙剂量减少≥50%(或≤500 mg/d)且骨化三醇剂量减少≥50%(或≤0.25 µg/d),同时白蛋白校正血钙正常或维持基线水平且不超过正常上限。

临床怎么用

  • 对于慢性甲状旁腺功能减退症成人患者,rhPTH(1-84)长期治疗可考虑用于改善血钙和尿钙等生化指标。
  • 治疗期间需监测血钙、尿钙、血磷及不良事件,尤其是低钙血症相关症状。

局限性

  • 开放标签扩展研究,无对照组,样本量较小(N=49),结果解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Conventional hypoparathyroidism treatment with oral calcium and active vitamin D is aimed at correcting hypocalcemia but does not address other physiologic defects caused by PTH deficiency. OBJECTIVE: To evaluate long-term safety and tolerability of recombinant human PTH (1-84) [rhPTH(1-84)]. DESIGN: Open-label extension study; 5-year interim analysis. SETTING: 12 US centers. PATIENTS: Adults (N = 49) with chronic hypoparathyroidism. INTERVENTION(S): rhPTH(1-84) 25 or 50 µg/d initially, with 25-µg adjustments permitted to a 100 µg/d maximum. MAIN OUTCOME MEASURE(S): Safety parameters; composite efficacy outcome was the proportion of patients with ≥50% reduction in oral calcium (or ≤500 mg/d) and calcitriol (or ≤0.25 µg/d) doses, and albumin-corrected serum calcium normalized or maintained compared with baseline, not exceeding upper limit of normal. RESULTS: Forty patients completed 60 months of treatment. Mean albumin-corrected serum calcium levels remained between 8.2 and 8.7 mg/dL. Between baseline and month 60, levels ± SD of urinary calcium, serum phosphorus, and calcium-phosphorus product decreased by 101.2 ± 236.24 mg/24 hours, 1.0 ± 0.78 mg/dL, and 8.5 ± 8.29 mg2/dL2, respectively. Serum creatinine level and estimated glomerular filtration rate were unchanged. Treatment-emergent adverse events (AEs) were reported in 48 patients (98.0%; hypocalcemia, 36.7%; muscle spasms, 32.7%; paresthesia, 30.6%; sinusitis, 30.6%; nausea, 30.6%) and serious AEs in 13 (26.5%). At month 60, 28 patients (70.0%) achieved the composite efficacy outcome. Bone turnover markers increased, peaked at ∼12 months, and then declined to values that remained above baseline. CONCLUSION: Treatment with rhPTH(1-84) for 5 years demonstrated a safety profile consistent with previous studies and improved key biochemical parameters.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Mannstadt M, Clarke BL, Bilezikian JP, et al. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. J Clin Endocrinol Metab. 2019. PMID: 31369089. doi:10.1210/jc.2019-01010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。